Mp87-05 superior efficacy of degarelix as neoadjuvant hormone therapy in control of acute genitourinary toxicity associated with radiation therapy for prostate cancer compared to lhrh agonist; a propensity-score matching analysis

Degarelix has been reported to offer superior control of lower urinary tract symptoms (LUTS) compared to luteinizing hormone-releasing hormone (LHRH) agonist. However, whether degarelix can reduce acute genitourinary toxicity associated with irradiation when used as neoadjuvant androgen-deprivation therapy (ADT) remains unclear. The aim of this study was to evaluate the efficacy of degarelix as neoadjuvant ADT followed by radiation therapy in the control of acute genitourinary toxicity compared to LHRH agonist.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Advanced (including  Drug Therapy) IV Source Type: research